Amarin Reports Strong Q1 2026 Results with Positive Operating Cash Flow and Settles Antitrust Class Actions
AMRN sits 48% above its 52-week low of $9.44.
Summary
Amarin reported improved Q1 2026 financial results, including a shift to positive operating cash flow and reduced net loss, driven by cost controls and international growth. The company also settled multiple antitrust class action lawsuits.
Key Events · Earnings and Guidance · AMRN
-
Achieved Positive Operating Cash Flow
Net cash provided by operating activities was $6.4 million for Q1 2026, a significant improvement from net cash used of $12.5 million in Q1 2025, indicating enhanced operational efficiency and financial stability.
-
Reduced Net Loss
The company reported a net loss of $10.5 million for Q1 2026, a reduction from a net loss of $15.7 million in Q1 2025, and basic/diluted loss per share improved to ($0.03) from ($0.04).
-
Revenue Growth Driven by International Partnerships
Total revenue increased by 7% to $45.1 million in Q1 2026. Licensing and royalty revenue surged by 84% to $1.8 million, and RoW product revenue significantly increased to $2.8 million, reflecting the success of the European partnering model and developing ex-U.S. markets.
-
Significant Reduction in Operating Expenses
Selling, general and administrative (SG&A) expenses decreased by 42% to $21.1 million, primarily due to cost savings from the Global Restructuring Plan initiated in June 2025.
Analysis · AMRN · Life Sciences
Amarin Corporation plc reported a significant financial turnaround in Q1 2026, achieving positive net cash flow from operating activities of $6.4 million, a substantial improvement from a net cash outflow of $12.5 million in the prior year period. This was driven by a 42% reduction in selling, general, and administrative (SG&A) expenses, reflecting the impact of the Global Restructuring Plan initiated in June 2025. Total revenue increased by 7% year-over-year to $45.1 million, with notable growth in licensing and royalty revenue (up 84%) and Rest of World (RoW) product revenue, indicating successful execution of its international partnering strategy. The company also announced a confidential settlement agreement for six antitrust class action lawsuits, removing a significant legal overhang. While gross margin decreased due to a shift in customer mix towards lower-margin partner sales, the overall financial health shows improvement and strategic progress. Ongoing patent litigation with Hikma at the Supreme Court and a lawsuit by the former CEO remain as notable risks.
At the time of this filing, AMRN was trading at $13.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $290.5M. The 52-week trading range was $9.44 to $20.90. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.